Change at the top for CDMOs
Two of the major global pharmaceutical CDMOs, Lonza and Alcami, have announced the appointments of new CEOs in early June. There have also been changes in senior positions at Corden Pharma and, imminently, at Cambrex.
Lonza swings to pharma
Lonza has announced results for 2019, in which its growth was entirely driven by the Pharma Biotech & Nutrition division on which it will base its future.
Lonza invests more in HPAPIs
Lonza is to expand high potency API (HPAPI) capacity at its main site at Visp, Switzerland, in response to demand.
